0001299933-15-001298.txt : 20150831 0001299933-15-001298.hdr.sgml : 20150831 20150831123049 ACCESSION NUMBER: 0001299933-15-001298 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150828 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20150831 DATE AS OF CHANGE: 20150831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CANNAPHARMARX, INC. CENTRAL INDEX KEY: 0001081938 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274635140 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27055 FILM NUMBER: 151084147 BUSINESS ADDRESS: STREET 1: ONE COLLINS DRIVE CITY: CARNEYS POINT STATE: NJ ZIP: 08069 BUSINESS PHONE: 720-939-1133 MAIL ADDRESS: STREET 1: ONE COLLINS DRIVE CITY: CARNEYS POINT STATE: NJ ZIP: 08069 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN DRAGON HOLDING CO. DATE OF NAME CHANGE: 20110125 FORMER COMPANY: FORMER CONFORMED NAME: CCVG, INC. DATE OF NAME CHANGE: 20101117 FORMER COMPANY: FORMER CONFORMED NAME: CONCORD VENTURES, INC. DATE OF NAME CHANGE: 20071003 8-K 1 htm_52349.htm LIVE FILING CannaPharmaRx, Inc. (Form: 8-K)  

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   August 28, 2015

CannaPharmaRx, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 000-27055 27-4635140
_____________________
(State or other jurisdiction 		_____________
(Commission 		______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
One Collins Drive, Suite 100, Carneys Point, New Jersey   08069
_________________________________
(Address of principal executive offices) 		  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   856-376-0500

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     
Item 5.07.
  Submission of Matters to a Vote of Security Holders.

On August 28, 2015, CannaPharmaRx, Inc., a Delaware corporation (the “Company”), held its 2015 Annual Meeting of Stockholders via telephonic conference call and at the Company’s headquarters at One Collins Drive, Suite 100, Carneys Point, New Jersey 08069-3640 (the “Annual Meeting”). At the Annual Meeting, at which a quorum was present, the stockholders of the Company voted on and approved the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on July 17, 2015:

(1) to elect seven directors;

(2) to conduct an advisory vote on executive compensation;

(3) to conduct an advisory vote on the frequency of future votes on executive compensation;

(4) to ratify the appointment of KLJ & Associates, LLP as the Company’s independent public accountants for the year ending December 31, 2015; and

(5) to transact any other business that may properly come before the meeting.

Only stockholders of record as of the close of business on July 10, 2015 were entitled to vote at the Annual Meeting. As of July 10, 2015, 17,959,621 shares of common stock of the Company (“Common Shares”) were outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 9,014,561 Common Shares were represented, in person or by proxy, constituting a quorum.

The votes with the proposals are set forth below.

(1) Elect the Directors of the Company to serve until the 2016 Annual Meeting:

The following nominees were elected as directors to serve until the 2016 Annual Meeting by the votes indicated below:

  

                                                                 
Name of Director Nominee
   For   Against   Abstain   Broker Non-Vote    
                             
Gerald E. Crocker
   8,994,549       12           20,000           —    
Robert “Bo” Liess
   8,394,561       600,000           20,000           —    
Wendy F. DiCicco
   8,994,561       —           20,000           —    
David Pohl
   8,994,561           —           20,000           —        
Alex Giaquinto, PhD
   8,994,561           —           20,000           —        
Elie Khalife
   8,994,561           —           20,000           —        
Steven Rule
   8,994,549           12           20,000           —        

(2) Advisory vote on executive compensation.  

                                 
For
      Against       Abstain       Broker Non-Vote
 
                               
8,158,549
        836,012           20,000         —

(3) Advisory vote on the frequency of future votes on executive compensation.  

                                     
One Year
      Two Years       Three Years       Abstain
 
                                   
5,995,759
        1,380,060           838,742           800,000  

(4) Ratification of the appointment of KLJ & Associates, LLP as the Company’s independent registered public accounting firm for Fiscal Year 2015.  

                             
For
      Against       Abstain       Broker Non-Vote
 
                           
8,994,561
      -         20,000         —

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    CannaPharmaRx, Inc.
          
August 31, 2015   By:   /s/ Gerald E. Crocker
       
        Name: Gerald E. Crocker
        Title: Chief Executive Officer and Director